3RM8
 
 | | AMCase in complex with Compound 2 | | 分子名称: | 2-methyl-3-{[4-(pyridin-2-yl)piperazin-1-yl]methyl}-1H-indole, Acidic mammalian chitinase | | 著者 | Olland, A. | | 登録日 | 2011-04-20 | | 公開日 | 2011-08-24 | | 最終更新日 | 2023-09-13 | | 実験手法 | X-RAY DIFFRACTION (1.8 Å) | | 主引用文献 | Identification and Characterization of Acidic Mammalian Chitinase Inhibitors
J.Med.Chem., 53, 2010
|
|
3RM4
 | | AMCase in complex with Compound 1 | | 分子名称: | 5-{4-[2-(4-bromophenoxy)ethyl]piperazin-1-yl}-4H-1,2,4-triazol-3-amine, Acidic mammalian chitinase | | 著者 | Olland, A. | | 登録日 | 2011-04-20 | | 公開日 | 2011-08-24 | | 最終更新日 | 2023-09-13 | | 実験手法 | X-RAY DIFFRACTION (1.9 Å) | | 主引用文献 | Identification and Characterization of Acidic Mammalian Chitinase Inhibitors
J.Med.Chem., 53, 2010
|
|
3RME
 | | AMCase in complex with Compound 5 | | 分子名称: | Acidic mammalian chitinase, GLYCEROL, N-ethyl-2-(4-methylpiperazin-1-yl)pyridine-3-carboxamide | | 著者 | Olland, A. | | 登録日 | 2011-04-20 | | 公開日 | 2011-08-24 | | 実験手法 | X-RAY DIFFRACTION (1.8 Å) | | 主引用文献 | Identification and Characterization of Acidic Mammalian Chitinase Inhibitors
J.Med.Chem., 53, 2010
|
|
3RM9
 | | AMCase in complex with Compound 3 | | 分子名称: | 4-(4-chlorophenyl)piperazine-1-carboximidamide, Acidic mammalian chitinase | | 著者 | Olland, A. | | 登録日 | 2011-04-20 | | 公開日 | 2011-08-24 | | 最終更新日 | 2023-09-13 | | 実験手法 | X-RAY DIFFRACTION (2.1 Å) | | 主引用文献 | Identification and Characterization of Acidic Mammalian Chitinase Inhibitors
J.Med.Chem., 53, 2010
|
|
6MAU
 | | Crystal structure of human BRD4(1) in complex with CN210 (compound 19) | | 分子名称: | 1-(4-{6-(3,5-dimethyl-1,2-oxazol-4-yl)-4-[(3S)-3-phenylmorpholin-4-yl]quinazolin-2-yl}-1H-pyrazol-1-yl)-2-methylpropan-2-ol, Bromodomain-containing protein 4, GLYCEROL | | 著者 | Nadupalli, A, Fontano, E, Connors, C.R, Chan, S.G, Olland, A.M, Lakshminarasimhan, D, White, A, Suto, R.K. | | 登録日 | 2018-08-28 | | 公開日 | 2019-04-03 | | 最終更新日 | 2024-03-13 | | 実験手法 | X-RAY DIFFRACTION (2.11 Å) | | 主引用文献 | Lead optimization and efficacy evaluation of quinazoline-based BET family inhibitors for potential treatment of cancer and inflammatory diseases.
Bioorg. Med. Chem. Lett., 29, 2019
|
|
